Evidence Layer · Updated September 14, 2026 Evidence-qualified answers to meta-analytic scientific questions, with scope and limitations.
Reported mLOY prevalence reflects the detection method, age distribution, and mutagenic exposures rather than tissue biology alone — e.g., ~1–2% in blood-derived biobank cancer cohorts, ~8% in prostate cancer overall, but roughly 5–10× higher in patients treated with radiotherapy.
Limitations: cross-tissue comparisons without harmonized thresholds and age adjustment are largely confounded; headline figures come from heterogeneous cohorts.
View full evidence →No meta-analysis could be completed: all supplied claim-level and clinical trial records concerned EGFR signaling and NSCLC therapeutics, with none addressing UAE crop wild relative taxa or phytochemical bioactivity.
Limitations: automated record collection silently diverged from the query domain, illustrating reproducibility risk in pipeline-driven evidence reviews; no conclusion about the original question is possible from the available records.
View full evidence →Separates radiation effect from age-related drift.
Tests whether blood and epithelial mLOY clones are concordant.
Evidence-backed answers are also available through MCP for Claude, Cursor, and other compatible AI tools.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.
Explore by Goal
Trending